HMEU:LSE:LSE-HSBC MSCI Europe UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 1499.2

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 652.47B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 650.46B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B

ETFs Containing HMEU:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.81% 56% F 58% F
Dividend Return 0.01% 27% F 20% F
Total Return 4.82% 55% F 58% F
Trailing 12 Months  
Capital Gain 6.77% 45% F 54% F
Dividend Return 0.03% 29% F 32% F
Total Return 6.79% 44% F 54% F
Trailing 5 Years  
Capital Gain 32.79% 53% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.79% 50% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.55% 57% F 62% D
Dividend Return 5.56% 56% F 61% D-
Total Return 0.01% 11% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 10.69% 64% D 78% C+
Risk Adjusted Return 52.01% 68% D+ 79% B-
Market Capitalization 0.17B 53% F 46% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.